<DOC>
	<DOCNO>NCT00127101</DOCNO>
	<brief_summary>This investigational study increase dosage determine safety/tolerability , efficacy histone deacetylase inhibitor combination Targretin patient cutaneous T-cell lymphoma patient fail least one prior systemic therapy .</brief_summary>
	<brief_title>An Investigational Study Histone Deacetylase ( HDAC ) Inhibitor Plus Targretin Cutaneous T-Cell Lymphoma Patients ( 0683-016 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Women men great equal 18 year age Advanced cutaneous Tcell lymphoma , stage IB high include Sezary Syndrome progressive , persistent , recurrent disease Failure least one systemic therapy , include Bexarotene ( Targretin ) Eastern Cooperative Oncology Group ( ECOG ) status less equal 2 ( measurement determine ability perform daily activity ) Patient investigational treatment precede 30 day Active hepatitis B C , history HIV Prior treatment HDAC inhibitor Patients must disease free prior malignancy great 5 year , except curatively treat basal cell squamous cell carcinoma skin carcinoma insitu cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>